Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment.
Level 3 - non-randomized controlled study
PK/PD mathematical modeling and simulation using pooled data from randomized controlled trials
PubMed 42022334 · doi:10.1002/trc2.70246
What was done
Researchers pooled plasma biomarker data (Aβ42/40 ratio, p-tau181, and GFAP) from Phase 2 (Study 201) and Phase 3 (Clarity AD) trials of lecanemab in early Alzheimer's disease. Using indirect response pharmacokinetic/pharmacodynamic (PK/PD) models linked to individual serum drug exposure, they simulated the effects of continuous biweekly dosing (10 mg/kg) over 4 years, treatment discontinuation after 18 months, and transitions to monthly dosing at 18, 24, or 30 months.
What was found
Model simulations showed that plasma biomarkers returned toward pretreatment baseline after lecanemab cessation with an average re-accumulation half-life of approximately 1 to 1.5 years, which was faster than amyloid plaque re-accumulation on PET. Transitioning to a monthly IV dosing regimen at 18 months stabilized plasma biomarker concentrations at levels reflecting continued biomarker suppression. The abstract reported no specific sample sizes, variance, or confidence intervals.
Why it matters
The findings suggest that ongoing therapy or monthly maintenance may be necessary to sustain biomarker improvements even after initial plaque clearance, and that plasma biomarkers may detect recurring pathology earlier than PET.
Limits
The conclusions for maintenance and discontinuation rely entirely on computational simulations rather than prospective clinical trials. The abstract omits the number of participants ($n$), confidence intervals around model parameters, and any direct assessment of clinical or cognitive outcomes under the alternative regimens.
Cited by
- contradicts Lecanemab lowered phosphorylated tau by 23% in clinical trials over nearly 7 years.